SCHEMBL4125327

SCHEMBL4125327

CN(NC(=O)c1cnn2c(-c3ccc(Cl)cc3F)c(-c3ccccc3Br)cnc12)c1ccccn1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 1/20 0.37
IRAK4 Q9NWZ3 8/20 0.35
NPC1 O15118 1/20 0.34
HPGD P15428 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
JAK2 O60674 3/20 0.33
JAK1 P23458 3/20 0.33
PDE2A O00408 2/20 0.33
PDE4A P27815 2/20 0.33
PDE4B Q07343 2/20 0.33
PDE4C Q08493 2/20 0.33
PDE4D Q08499 2/20 0.33
GRM4 Q14833 1/20 0.33
PDE10A Q9Y233 1/20 0.33
TYK2 P29597 2/20 0.33
JAK3 P52333 2/20 0.33
PYGL P06737 1/20 0.33
SCN9A Q15858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4120614 0.89 SMN1; SMN2 (0.35) IRAK4NPC1RAB9ASMN1; SMN2JAK2
SCHEMBL4116611 0.88 GABRA1 (0.35) GRIN2BIRAK4JAK2JAK1PDE2A
SCHEMBL4115866 0.87 GRIN2B (0.34) GRIN2BNPC1HPGDRAB9ASMN1; SMN2
SCHEMBL4126386 0.82 KMO (0.39) GRIN2BIRAK4NPC1HPGDRAB9A
SCHEMBL4129733 0.81 PDE4B (0.37) JAK2JAK1PDE4APDE4BPDE4C
SCHEMBL4121225 0.80 JAK2 (0.36) IRAK4NPC1RAB9ASMN1; SMN2JAK2
SCHEMBL4108378 0.77 KDM4E (0.38) IRAK4NPC1RAB9ASMN1; SMN2JAK2
SCHEMBL4112786 0.75 GABRA1 (0.35) GRIN2BHPGDSMN1; SMN2PDE2AGRM4
SCHEMBL4118722 0.75 LMNA (0.39) SCN9A
SCHEMBL2086291 0.74 CNR1 (0.40) IRAK4JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
EP-1945220-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-23 EP disclosed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD GRIN2B 1517/4885IRAK4 2949/4885NPC1 3153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.